Accepting New Patients
Telehealth
Kimberly Jean Koval, APN
Hematology, Medical Oncology
Female
Want to know your insurance options?
See Full ListAbout me
Kimberly Jean Koval, MSN, RN, ANP-C, CCRN, is an advanced nurse practitioner at Advanced Care Oncology & Hematology Associates (ACOHA). She has proven strengths in primary and acute patient care who achieved her masters of science degree from Fairleigh Dickenson University. Kimberly has an exceptional capacity to multitask: manage numerous, often competing priorities with ease while providing excellent, individualized patient care.
Kimberly has an acute ability to assess patients frequently for changes in status and monitoring multiple medication infusions and vital signs. She is a meticulous team player and responds to rapid response calls as she expertly assists in treatment assessments for patients to determine the best outcome and needs of care.
SPECIALTIES
Hematology
Medical Oncology
AFFILIATIONS
Accountable Care Organization
Atlantic Medical Group
Chilton Medical Center
Hackettstown Medical Center
Morristown Medical Center
Newton Medical Center
Overlook Medical Center
Where to see me
at Morristown Medical Center
Carol G. Simon Cancer Center
at Morristown Medical Center Health Pavilion
Insurance
Please contact the practice to confirm your health plan is accepted.
Aetna
Aetna Better Health
AHS PPO
Amerihealth
Amerihealth Caritas
Brighton Create
Brighton Healthplan Solutions
Centivo
Cigna
ClaimDoc LLC
Education & Experience
TRAINING
Fairleigh Dickenson University
Post Graduate Education
BOARD CERTIFICATIONS
Patient Reviews
4.8
- 5.0Aug 31, 2026Provider extremely friendly excellent knowledge had humor easy to talk to.
- 5.0Aug 20, 2026Kim Koval is a pleasure to deal with. I understand that in an oncology office, many patients are dealing with A LOT!!! I make it a point to be patient with any delays in being seen at my appt. time. This is a very good group of employees at ACO & H Assoc.
- 5.0Aug 13, 2026Very satisfied
- 5.0Aug 13, 2026Very satisfied
- 5.0Aug 9, 2026Very good.